Pharmacology of NMDA receptors

Biology of the NMDA Receptor

Volumn , Issue , 2008, Pages 257-281

  Monaghan, Daniel T ^a   Jane, David E ^b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85057925092     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (182)

1. Watkins, J.C., Pharmacology of excitatory amino acid transmitters, Adv. Biochem. Psychopharmacol., 29, 205, 1981.
2. Biscoe, T.J. et al., D-alpha-aminoadipate as a selective antagonist of amino acid-induced and synaptic excitation of mammalian spinal neurones, Nature, 270, 743, 1977.
3. Davies, J. and Watkins, J.C., Actions of D and L forms of 2-amino-5-phosphonova-lerate and 2-amino-4-phosphonobutyrate in the cat spinal cord, Brain Res., 235, 378, 1982.
4. Nakanishi, S., Molecular diversity of glutamate receptors and implications for brain function, Science, 258, 597, 1992.
5. Mori, H. and Mishina, M., Structure and function of the NMDAR channel, Neuropharmacology, 34, 1219, 1995.
6. Seeburg, P.H. et al., The NMDAR channel: molecular design of a coincidence detector, Recent Prog. Horm. Res., 50, 19, 1995.
7. Kuryatov, A. et al., Mutational analysis of the glycine-binding site of the NMDAR: structural similarity with bacterial amino acid-binding proteins, Neuron, 12, 1291, 1994.
8. Hirai, H. et al., The glycine binding site of the N-methyl-D-aspartate receptor subunit NR1: identification of novel determinants of co-agonist potentiation in the extracellular M3-M4 loop region, Proc. Natl. Acad. Sci. USA, 93, 6031, 1996.
9. Anson, L.C. et al., Identification of amino acid residues of the NR2A subunit that control glutamate potency in recombinant NR1/NR2A NMDARs, J. Neurosci., 18, 581, 1998.
10. Laube, B. et al., Molecular determinants of agonist discrimination by NMDAR subunits: analysis of the glutamate binding site on the NR2B subunit, Neuron, 18, 493, 1997.
11. Laube, B., Kuhse, J., and Betz, H., Evidence for a tetrameric structure of recombinant NMDARs, J. Neurosci., 18, 2954, 1998.
12. Chatterton, J.E. et al., Excitatory glycine receptors containing the NR3 family of NMDAR subunits, Nature, 415, 793, 2002.
13. Sugihara, H. et al., Structures and properties of seven isoforms of the NMDAR generated by alternative splicing, Biochem. Biophys. Res. Commun., 185, 826, 1992.
14. Hollmann, M. et al., Zinc potentiates agonist-induced currents at certain splice variants of the NMDAR, Neuron, 10, 943, 1993.
15. Traynelis, S.F., Hartley, M., and Heinemann, S.F., Control of proton sensitivity of the NMDAR by RNA splicing and polyamines, Science, 268, 873, 1995.
16. Dingledine, R., Myers, S.J., and Nicholas, R.A., Molecular biology of mammalian amino acid receptors, FASEB J., 4, 2636, 1990.
17. O’Hara, PJ. et al., The ligand-binding domain in metabotropic glutamate receptors is related to bacterial periplasmic binding proteins, Neuron, 11, 41, 1993.
18. Masuko, T. et al., A regulatory domain (R1-R2) in the amino terminus of the N-methyl-D-aspartate receptor: effects of spermine, protons, and ifenprodil, and structural similarity to bacterial leucine/isoleucine/valine binding protein, Mol. Pharmacol., 55, 957, 1999.
19. 2+ binding to NMDARs, Neuron, 25, 683, 2000.
20. Rachline, J. et al., The micromolar zinc-binding domain on the NMDAR subunit NR2B, J. Neurosci., 25, 308, 2005.
21. Stern-Bach, Y. et al., Agonist selectivity of glutamate receptors is specified by two domains structurally related to bacterial amino acid-binding proteins, Neuron, 13, 1345, 1994.
22. Kuner, T., Seeburg, P.H., and Guy, H.R., A common architecture for K+ channels and ionotropic glutamate receptors?, Trends Neurosci., 26, 27, 2003.
23. Zhorov, B.S. and Tikhonov, D.B., Potassium, sodium, calcium and glutamate-gated channels: pore architecture and ligand action, J. Neurochem., 88, 782, 2004.
24. Curtis, D.R. and Watkins, J.C., The excitation and depression of spinal neurones by structurally related amino acids, J. Neurochem., 6, 117, 1960.
25. Furukawa, H. et al., Subunit arrangement and function in NMDARs, Nature, 438, 185, 2005.
26. Lunn, M.L. et al., Three-dimensional structure of the ligand-binding core of GluR2 in complex with the agonist (S)-ATPA: implications for receptor subunit selectivity, J. Med. Chem. 46, 872, 2003.
27. Brown, J.C., et al., [3H]homoquinolinate binds to a subpopulation of NMDARs and to a novel binding site, J. Neurochem., 71, 1464, 1998.
28. Shinozaki, H. et al., A conformationally restricted analogue of L-glutamate, the (2S,3R,4S) isomer of L-alpha-(carboxycyclopropyl)glycine, activates the NMDA-type receptor more markedly than NMDA in the isolated rat spinal cord, Brain Res., 480, 355, 1989.
29. 2+ increase, Eur. J. Pharmacol., 211, 195, 1992.
30. Sunter, D.C., Edgar, G.E., Pook, P.C.-K., Howard, J.A.K., Udvarhelyi, P.M., and Watkins, J.C., Actions of the four isomers of 1-aminocyclopentane-1,3-dicarboxylate (ACPD) in the hemisected spinal cord of the neonatal rat, Br. J. Pharmacol., 104, 377P, 1991.
31. Allan, R.D. et al., Synthesis and activity of a potent N-methyl-D-aspartic acid agonist, trans-1-aminocyclobutane-1,3-dicarboxylic acid, and related phosphonic and carboxylic acids, J. Med. Chem., 33, 2905, 1990.
32. Lanthorn, T.H. et al., Cis-2,4-methanoglutamate is a potent and selective N-methyl-D-aspartate receptor agonist, Eur. J. Pharmacol., 182, 397, 1990.
33. Jane, D.E., Olverman, H.J., and Watkins, J.C., Agonists and Competitive Antagonists: Structure-Activity and Molecular Modelling Studies, Watkins, J.C., Ed., Oxford University Press, Oxford, 1994, p. 31.
34. Hall, J.G., McLennan, H., and Wheal, H.V., The actions of certain amino acids as neuronal excitants J. Physiol., 272, 52P, 1977.
35. Biscoe, T.J. et al., D-alpha-aminoadipate, alpha, epsilon-diominopimelic acid and HA-966 as antagonists of amino acid-induced and synaptic excitation of mammalian spinal neurones in vivo, Brain. Res., 148, 543, 1978.
36. Evans, R.H., Francis, A.A., and Watkins, J.C., Mg2+-like selective antagonism of excitatory amino acid-induced responses by alpha, epsilon-diaminopimelic acid, D-alpha-aminoadipate and HA-966 in isolated spinal cord of frog and immature rat, Brain Res., 148, 536, 1978.
37. Davies, J. et al., Differential activation and blockade of excitatory amino acid receptors in the mammalian and amphibian central nervous systems, Comp. Biochem. Physiol. C., 72, 211, 1982.
38. Davies, J. et al., 2-Amino-5-phosphonovalerate (2APV), a potent and selective antagonist of amino acid-induced and synaptic excitation, Neurosci. Lett., 21, 77, 1981.
39. Evans, R.H. et al., The effects of a series of omega-phosphonic alpha-carboxylic amino acids on electrically evoked and excitant amino acid-induced responses in isolated spinal cord preparations, Br. J. Pharmacol., 75, 65, 1982.
40. Olverman, H.J. et al., Structure/activity relations of N-methyl-D-aspartate receptor ligands as studied by their inhibition of [3H]D-2-amino-5-phosphonopentanoic acid binding in rat brain membranes, Neuroscience, 26, 17, 1988.
41. Ornstein, P.L. et al., 4-(Tetrazolylalkyl)piperidine-2-carboxylic acids: potent and selective N-methyl-D-aspartic acid receptor antagonists with a short duration of action, J. Med. Chem., 34, 90, 1991.
42. Lehmann, J. et al., CGS 19755, a selective and competitive N-methyl-D-aspartate-type excitatory amino acid receptor antagonist, J. Pharmacol. Exp. Ther., 246, 65, 1988.
43. Davies, J. et al., CPP, a new potent and selective NMDA antagonist: depression of central neuron responses, affinity for [3H]D-AP5 binding sites on brain membranes and anticonvulsant activity, Brain Res., 382, 169, 1986.
44. Harris, E.W. et al., Action of 3-[(+/-)-2-carboxypiperazin-4-yl]-propyl-1-phosphonic acid (CPP): a new and highly potent antagonist of N-methyl-D-aspartate receptors in the hippocampus, Brain Res., 382, 174, 1986.
45. Lowe, D.A. et al., The pharmacology of SDZ EAA 494, a competitive NMDA antagonist, Neurochem. Int., 25, 583, 1994.
46. Ferkany, J.W. et al., Pharmacological profile of NPC 17742 [2R,4R,5S-(2-amino-4,5-(1, 2-cyclohexyl)-7-phosphonoheptanoic acid)], a potent, selective and competitive N-methyl-D-aspartate receptor antagonist, J. Pharmacol. Exp. Ther., 264, 256, 1993.
47. Urwyler, S. et al., Biphenyl-derivatives of 2-amino-7-phosphono-heptanoic acid, a novel class of potent competitive N-methyl-D-aspartate receptor antagonists II. Pharmacological characterization in vivo, Neuropharmacology, 35, 655, 1996.
48. Fagg, G.E. et al., CGP 37849 and CGP 39551: novel and potent competitive N-methyl-D-aspartate receptor antagonists with oral activity, Br. J. Pharmacol., 99, 791, 1990.
49. Baudy, R.B. et al., Potent quinoxaline-spaced phosphono a-amino acids of the AP-6 type as competitive NMDA antagonists: synthesis and biological evaluation, J. Med. Chem, 36, 331, 1993.
50. Heckendorn, R. et al., Synthesis and binding properties of 2-amino-5-phosphono-3-pentenoic acid photoaffinity ligands as probes for the glutamate recognition site of the NMDAR, J. Med. Chem., 36, 3721, 1993.
51. Ornstein, P.L. et al., 6-substituted decahydroisoquinoline-3-carboxylic acids as potent and selective conformationally constrained NMDAR antagonists, J. Med. Chem., 35, 3547, 1992.
52. Beaton, J.A., Stemsrud, K., and Monaghan, D.T., Identification of a novel N-methyl-D-aspartate receptor population in the rat medial thalamus, J. Neurochem., 59, 754, 1992.
53. Buller, A.L. and Monaghan, D.T., Pharmacological heterogeneity of NMDARs: characterization of NR1a/NR2D heteromers expressed in Xenopus oocytes, Eur. J. Pharmacol., 320, 87, 1997.
54. Olverman, H.J., Jones, A.W., and Watkins, J.C., [3H]D-2-amino-5-phosphonopen-tanoate as a ligand for N-methyl-D-aspartate receptors in the mammalian central nervous system, Neuroscience, 26, 1, 1988.
55. Olverman, H.J., Jones, A.W., and Watkins, J.C., L-glutamate has higher affinity than other amino acids for [3H]-D-AP5 binding sites in rat brain membranes, Nature, 307, 460, 1984.
56. Murphy, D.E. et al., Characterization of the binding of [3H]-CGS 19755: a novel N-methyl-D-aspartate antagonist with nanomolar affinity in rat brain, Br. J. Pharmacol., 95, 932, 1988.
57. Olverman, H.J. et al., [3H]CPP, a new competitive ligand for NMDARs, Eur. J. Pharmacol., 131, 161, 1986.
58. Sills, M.A. et al., [3H]CGP 39653: a new N-methyl-D-aspartate antagonist radioligand with low nanomolar affinity in rat brain, Eur. J. Pharmacol., 192, 19, 1991.
59. Monaghan, D.T., Andaloro, V.J., and Skifter, D.A., Molecular determinants of NMDAR pharmacological diversity, Prog. Brain Research, 1998.
60. Gaoni, Y. et al., Synthesis, NMDAR antagonist activity, and anticonvulsant action of 1-aminocyclobutanecarboxylic acid derivatives, J. Med. Chem., 37, 4288, 1994.
61. Muller, W. et al., Synthesis and N-methyl-D-aspartate (NMDA) antagonist properties of the enantiomers of a-amino-5-(phosphonomethyl)[1,1’-biphenyl]-3-propranoic acid: use of a new chiral glycine derivative, Helv. Chim. Acta., 75, 855, 1992.
62. Hutchison, A.J. et al., 4-(Phosphonoalkyl)- and 4-(phosphonoalkenyl)-2-piperidin-ecarboxylic acids: synthesis, activity at N-methyl-D-aspartic acid receptors, and anticonvulsant activity, J. Med. Chem., 32, 2171, 1989.
63. Dorville, A. et al., Preferred antagonist binding state of the NMDAR: synthesis, pharmacology, and computer modeling of (phosphonomethyl)phenylalanine derivatives, J. Med. Chem., 35, 2551, 1992.
64. Ortwine, D.F. et al., Generation of N-methyl-D-aspartate agonist and competitive antagonist pharmacophore models: design and synthesis of phosphonoalkyl-substi-tuted tetrahydroisoquinolines as novel antagonists, J. Med. Chem., 35, 1345, 1992.
65. Kinarsky, L. et al., Identification of subunit- and antagonist-specific amino acid residues in the N-Methyl-D-aspartate receptor glutamate-binding pocket, J. Pharmacol. Exp. Ther, 313, 1066, 2005.
66. Monyer, H. et al., Developmental and regional expression in the rat brain and functional properties of four NMDARs, Neuron, 12, 529, 1994.
67. Monyer, H. et al., Heteromeric NMDARs: molecular and functional distinction of subtypes, Science, 256, 1217, 1992.
68. Ishii, T. et al., Molecular characterization of the family of the N-methyl-D-aspartate receptor subunits, J. Biol. Chem., 268, 2836, 1993.
69. Ikeda, K. et al., Cloning and expression of the epsilon 4 subunit of the NMDAR channel, FEBS Lett, 313, 34, 1992.
70. Kutsuwada, T. et al., Molecular diversity of the NMDAR channel, Nature, 358, 36, 1992.
71. Nakanishi, N., Axel, R., and Shneider, N.A., Alternative splicing generates functionally distinct N-methyl-D-aspartate receptors, Proc. Natl. Acad. Sci. USA, 89, 8552, 1992.
72. Behe, P. et al., Determination of NMDA NR1 subunit copy number in recombinant NMDARs, Proc. R. Soc. Lond. B. Biol. Sci., 262, 205, 1995.
73. Das, S. et al., Increased NMDA current and spine density in mice lacking the NMDAR subunit NR3A, Nature, 393, 377, 1998.
74. Sheng, M. et al., Changing subunit composition of heteromeric NMDARs during development of rat cortex, Nature, 368, 144, 1994.
75. Chazot, P.L. and Stephenson, F.A., Molecular dissection of native mammalian forebrain NMDARs containing the NR1 C2 exon: direct demonstration of NMDARs comprising NR1, NR2A, and NR2B subunits within the same complex, J. Neurochem., 69, 2138, 1997.
76. Dunah, A.W. et al., Subunit composition of N-methyl-D-aspartate receptors in the central nervous system that contain the NR2D subunit, Mol. Pharmacol., 53, 429, 1998.
77. Benveniste, M. and Mayer, M.L., Kinetic analysis of antagonist action at N-methyl-D-aspartic acid receptors. Two binding sites each for glutamate and glycine, Biophys. J., 59, 560, 1991.
78. Honer, M. et al., Differentiation of glycine antagonist sites of N-methyl-D-aspartate receptor subtypes. Preferential interaction of CGP 61594 with NR1/2B receptors, J. Biol. Chem., 273, 11158, 1998.
79. Monaghan, D.T. et al., Two classes of N-methyl-D-aspartate recognition sites: differential distribution and differential regulation by glycine, Proc. Natl. Acad. Sci. USA, 85, 9836, 1988.
80. Monaghan, D.T. and Beaton, J.A., Quinolinate differentiates between forebrain and cerebellar NMDARs, Eur. J. Pharmacol., 194, 123, 1991.
81. Buller, A.L. et al., The molecular basis of NMDAR subtypes: native receptor diversity is predicted by subunit composition, J. Neurosci., 14, 5471, 1994.
82. Christie, J.M., Jane, D.E., and Monaghan, D.T., Native N-methyl-D-aspartate receptors containing NR2A and NR2B subunits have pharmacologically distinct competitive antagonist binding sites, J. Pharmacol. Exp. Ther., 292, 1169, 2000.
83. Laurie, D.J. and Seeburg, P.H., Ligand affinities at recombinant N-methyl-D-aspartate receptors depend on subunit composition, Eur. J. Pharmacol., 268, 335, 1994.
84. Watanabe, M. et al., Distinct spatio-temporal distributions of the NMDAR channel subunit mRNAs in the brain, Ann. NY Acad. Sci., 707, 463, 1993.
85. Andaloro, V.J. et al., Pharmacology of NMDAR subtypes, Soc. Neurosci. Abstr, 604, 1996.
86. Feng, B. et al., The effect of competitive antagonist chain length on NMDAR subunit selectivity, Neuropharmacology, 48, 354, 2005.
87. Feng, B. et al., Structure-activity analysis of a novel NR2C/NR2D-preferring NMDAR antagonist: 1-(phenanthrene-2-carbonyl) piperazine-2,3-dicarboxylic acid, Br. J. Pharmacol., 141, 508, 2004.
88. Morley, R.M. et al., Synthesis and pharmacology of N1-substituted piperazine-2,3-dicarboxylic acid derivatives acting as NMDAR antagonists, J. Med. Chem, 48, 2627, 2005.
89. Hrabetova, S. et al., Distinct NMDAR subpopulations contribute to long-term potentiation and long- term depression induction, J. Neurosci. (Online), 20, RC81, 2000.
90. Lozovaya, N.A. et al., Extrasynaptic NR2B and NR2D subunits of NMDARs shape superslow afterburst EPSC in rat hippocampus, J. Physiol., 558, 451, 2004.
91. Auberson, Y.P. et al., 5-Phosphonomethylquinoxalinediones as competitive NMDAR antagonists with a preference for the human 1A/2A, rather than 1A/2B receptor composition, Bioorg. Med. Chem. Lett, 12, 1099, 2002.
92. Massey, PV. et al., Differential roles of NR2A and NR2B-containing NMDARs in cortical long-term potentiation and long-term depression, J. Neurosci, 24, 7821, 2004.
93. Berberich, S. et al., Lack of NMDAR subtype selectivity for hippocampal long-term potentiation, J. Neurosci., 25, 6907, 2005.
94. Frizelle, P.A., Chen, P.E., and Wyllie, D.J., Equilibrium constants for NVP-AAM077 acting at recombinant NR1/NR2A and NR1/NR2B NMDARs: implications for studies of synaptic transmission, Mol. Pharmacol., 2006.
95. Erreger, K. et al., Subunit-specific agonist activity at NR2A, NR2B, NR2C, and NR2D containing N-methyl-D-aspartate glutamate receptors, Mol. Pharmacol, 2007.
96. Johnson, J.W. and Ascher, P., Glycine potentiates the NMDA response in cultured mouse brain neurons, Nature, 325, 529, 1987.
97. Kleckner, N.W. and Dingledine, R., Requirement for glycine in activation of NMDA-receptors expressed in Xenopus oocytes, Science, 241, 835, 1988.
98. Danysz, W. and Parsons, A.C., Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications, Pharmacol. Rev., 50, 597, 1998.
99. Leeson, P.D. and Iversen, L.L., The glycine site on the NMDAR: structure-activity relationships and therapeutic potential, J. Med. Chem, 37, 4053, 1994.
100. Watson, G.B. and Lanthorn, T.H., Pharmacological characteristics of cyclic homologues of glycine at the N-methyl-D-aspartate receptor-associated glycine site, Neuropharmacology, 29, 727, 1990.
101. Marvizon, J.C., Lewin, A.H., and Skolnick, P., 1-Aminocyclopropane carboxylic acid: a potent and selective ligand for the glycine modulatory site of the N-methyl-D-aspartate receptor complex, J. Neurochem., 52, 992, 1989.
102. Hood, W.F. et al., 1-Aminocyclobutane-1-carboxylate (ACBC): a specific antagonist of the N- methyl-D-aspartate receptor coupled glycine receptor, Eur. J. Pharmacol., 161, 281, 1989.
103. Javitt, D.C., Ionotropic glutamate receptors as therapeutic targets, in Schizophrenia, F.P. Graham Publishing, Johnson City, TN, 2002, p. 151.
104. Leeson, P.D. et al., Derivatives of 1-hydroxy-3-aminopyrrolidin-2-one (HA-966). Partial agonists at the glycine site of the NMDAR, Bioorg. Med. Chem. Lett., 3, 71, 1993.
105. Inanobe, A., Furukawa, H., and Gouaux, E., Mechanism of partial agonist action at the NR1 subunit of NMDARs, Neuron, 47, 71, 2005.
106. Hogner, A. et al., Competitive antagonism of AMPA receptors by ligands of different classes: crystal structure of ATPO bound to the GluR2 ligand-binding core, in comparison with DNQX, J. Med. Chem. 46, 214, 2003.
107. Armstrong, N. and Gouaux, E., Mechanisms for activation and antagonism of an AMPA-sensitive glutamate receptor: crystal structures of the GluR2 ligand binding core, Neuron, 28, 165, 2000.
108. Watson, G.B. et al., Kynurenate antagonizes actions of N-methyl-D-aspartate through a glycine sensitive receptor, Neurosci. Res. Commun., 2, 169, 1988.
109. Kessler, M. et al., A glycine site associated with N-methyl-D-aspartic acid receptors: characterization and identification of a new class of antagonists, J. Neurochem., 52, 1319, 1989.
110. Honore, T. et al., Quinoxalinediones: potent competitive non-NMDA glutamate receptor antagonists, Science, 241, 701, 1988.
111. Birch, P.J., Grossman, C.J., and Hayes, A.G., 6,7-Dinitro-quinoxaline-2,3-dion and 6-nitro,7-cyano-quinoxaline-2,3-dion antagonise responses to NMDA in the rat spinal cord via an action at the strychnine-insensitive glycine receptor, Eur. J. Pharmacol., 156, 177, 1988.
112. Leeson, P.D. et al., Kynurenic acid derivatives. Structure-activity relationships for excitatory amino acid antagonism and identification of potent and selective antagonists at the glycine site on the N-methyl-D-aspartate receptor, J. Med. Chem., 34, 1243, 1991.
113. Leeson, P.D. et al., 4-Amido-2-carboxytetrahydroquinolines. Structure-activity relationships for antagonism at the glycine site of the NMDAR, J. Med. Chem., 35, 1954, 1992.
114. Kulagowski, J.J. et al., 3′-(Arylmethyl)- and 3′-(aryloxy)-3-phenyl-4-hydroxyquinolin-2(1H)-ones: orally active antagonists of the glycine site on the NMDAR, J. Med. Chem, 37, 1402, 1994.
115. Di Fabio, R. et al., Substituted indole-2-carboxylates as in vivo potent antagonists acting as the strychnine-insensitive glycine binding site, J. Med. Chem., 40, 841, 1997.
116. Carignani, C. et al., NMDAR subunit characterization of the glycine site antagonist GV196771A and its action on the spinal cord wind-up, Naun. Schmied. Arch. Pharmacol., 358, P1119, 1998.
117. Cai, S.X. et al., Structure-activity relationships of alkyl- and alkoxy-substituted 1,4-dihydroquinoxaline-2,3-diones: potent and systemically active antagonists for the glycine site of the NMDAR, J. Med. Chem., 40, 730, 1997.
118. Auberson, Y.P. et al., N-phosphonoalkyl-5-aminomethylquinoxaline-2,3-diones: in vivo active AMPA and NMDA(glycine) antagonists, Bioorg. Med. Chem. Lett., 9, 249, 1999.
119. Nikam, S.S. et al., Design and synthesis of novel quinoxaline-2,3-dione AMPA/GlyN receptor antagonists: amino acid derivatives, J. Med. Chem., 42, 2266, 1999.
120. Bigge, C.F. et al., Synthesis of 1,4,7,8,9,10-hexahydro-9-methyl-6-nitropyrido[3,4-f]-quinoxaline-2,3-dione and related quinoxalinediones: characterization of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (and N-methyl-D-aspartate) receptor and anticonvulsant activity, J. Med. Chem., 38, 3720, 1995.
121. Furukawa, H. and Gouaux, E., Mechanisms of activation, inhibition and specificity: crystal structures of the NMDAR NR1 ligand-binding core, EMBO J., 22, 2873, 2003.
122. Kew, J.N. and Kemp, J.A., Ionotropic and metabotropic glutamate receptor structure and pharmacology, Psychopharmacology, 179, 4, 2005.
123. Bare, T.M. et al., Pyridazinoquinolinetriones as NMDA glycine site antagonists with oral antinociceptive activity in a model of neuropathic pain, J. Med. Chem., 50, 3113, 2007.
124. 3H]CGP 61594, the first photoaffinity ligand for the glycine site of NMDARs, Neuropharmacology, 38, 233, 1999.
125. Buller, A.L. et al., Glycine modulates ethanol inhibition of heteromeric N-methyl-D-aspartate receptors expressed in Xenopus oocytes, Mol. Pharmacol., 48, 717, 1995.
126. Sasaki, Y.F. et al., Characterization and comparison of the NR3A subunit of the NMDAR in recombinant systems and primary cortical neurons, J. Neurophysiol., 87, 2052, 2002.
127. Yao, Y. and Mayer, M.L., Characterization of a soluble ligand binding domain of the NMDAR regulatory subunit NR3A, J. Neurosci., 26, 4559, 2006.
128. Madry, C. et al., Principal role of NR3 subunits in NR1/NR3 excitatory glycine receptor function, Biochem. Biophys. Res. Commun., 354, 102, 2007.
129. Awobuluyi, M. et al., Subunit-specific roles of glycine-binding domains in activation of NR1/NR3 N-methyl-D-aspartate receptors, Mol. Pharmacol,. 71, 112, 2007.
130. Nilsson, A. et al., Characterisation of the human NMDAR subunit NR3A glycine binding site, Neuropharmacol., 52, 1151, 2007.
131. Karadottir, R. et al., NMDARs are expressed in oligodendrocytes and activated in ischaemia, Nature, 438, 1162, 2005.
132. Micu, I. et al., NMDARs mediate calcium accumulation in myelin during chemical ischaemia, Nature, 439, 988, 2006.
133. Salter, M.G. and Fern, R., NMDARs are expressed in developing oligodendrocyte processes and mediate injury, Nature, 438, 1167, 2005.
134. Sacaan, A.I. and Johnson, K.M., Spermine enhances binding to the glycine site associated with the N- methyl-D-aspartate receptor complex, Mol. Pharmacol., 36, 836, 1989.
135. McGurk, J.F., Bennett, M.V., and Zukin, R.S., Polyamines potentiate responses of N-methyl-D-aspartate receptors expressed in Xenopus oocytes, Proc. Natl. Acad. Sci. USA, 87, 9971, 1990.
136. Ransom, R.W. and Deschenes, N.L., Polyamines regulate glycine interaction with the N-methyl-D-aspartate receptor, Synapse, 5, 294, 1990.
137. Benveniste, M. and Mayer, M.L., Multiple effects of spermine on N-methyl-D-aspartic acid receptor responses of rat cultured hippocampal neurones, J. Physiol., 464, 131, 1993.
138. 3H]MK-801 binding to the N-methyl-D-aspartate receptor-ion channel complex by L-glutamate, glycine, and polyamines, J. Neurochem., 51, 830, 1988.
139. McBain, C.J. and Mayer, M.L., N-methyl-D-aspartic acid receptor structure and function, Physiol. Rev., 74, 723, 1994.
140. Williams, K., Interactions of polyamines with ion channels, Biochem. J., 325, 289, 1997.
141. Durand, G.M., Bennett, M.V., and Zukin, R.S., Splice variants of the N-methyl-D-aspartate receptor NR1 identify domains involved in regulation by polyamines and protein kinase C, Proc. Natl. Acad. Sci. USA, 90, 6731, 1993.
142. Zheng, X. et al., Mutagenesis rescues spermine and Zn2+ potentiation of recombinant NMDARs, Neuron, 12, 811, 1994.
143. Williams, K. et al., An acidic amino acid in the N-methyl-D-aspartate receptor that is important for spermine stimulation, Mol. Pharmacol., 48, 1087, 1995.
144. Williams, K. et al., Sensitivity of the N-methyl-D-aspartate receptor to polyamines is controlled by NR2 subunits, Mol. Pharmacol., 45, 803, 1994.
145. Williams, K., Pharmacological properties of recombinant N-methyl-D-aspartate (NMDA) receptors containing the epsilon 4 (NR2D) subunit, Neurosci. Lett., 184, 181, 1995.
146. Zhang, L. et al., Spermine potentiation of recombinant N-methyl-D-aspartate receptors is affected by subunit composition, Proc. Natl. Acad. Sci. USA, 91, 10883, 1994.
147. Carter, C., Rivy, J.P., and Scatton, B., Ifenprodil and SL 82.0715 are antagonists at the polyamine site of the N-methyl-D-aspartate (NMDA) receptor, Eur. J. Pharmacol., 164, 611, 1989.
148. Legendre, P. and Westbrook, G.L., Ifenprodil blocks N-methyl-D-aspartate receptors by a two-component mechanism, Mol. Pharmacol., 40, 289, 1991.
149. Williams, K., Ifenprodil discriminates subtypes of the N-methyl-D-aspartate receptor: selectivity and mechanisms at recombinant heteromeric receptors, Mol. Pharmacol., 44, 851, 1993.
150. Galli, A. and Mori, F., Acetylcholinesterase inhibition and protection by dizocilpine (MK-801) enantiomers, J. Pharm. Pharmacol., 48, 71, 1996.
151. Gallagher, M.J. et al., Interactions between ifenprodil and the NR2B subunit of the N-methyl-D-aspartate receptor, J. Biol. Chem., 271, 9603, 1996.
152. Gallagher, M.J., Huang, H., and Lynch, D.R., Modulation of the N-methyl-D-aspartate receptor by haloperidol: NR2B-specific interactions, J. Neurochem., 70, 2120, 1998.
153. Chenard, B.L. et al., (1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperid-ino)-1-propanol: a potent new neuroprotectant which blocks N-methyl-D-aspartate responses, J. Med. Chem., 38, 3138, 1995.
154. Fischer, G. et al., Ro 25-6981, a highly potent and selective blocker of N-methyl-D-aspartate receptors containing the NR2B subunit. Characterization in vitro, J. Pharmacol. Exp. Ther., 283, 1285, 1997.
155. Layton, M.E., Kelly, M.J., and Rodzinak, K.J., Recent advances in the development of NR2B subtype-selective NMDAR antagonists, Curr. Top. Med. Chem., 6, 697, 2006.
156. McCauley, J.A. et al., NR2B-selective N-methyl-D-aspartate antagonists: synthesis and evaluation of 5-substituted benzimidazoles, J. Med. Chem., 47, 2089, 2004.
157. Wright, J.L. et al., Subtype-selective N-methyl-D-aspartate receptor antagonists: synthesis and biological evaluation of 1-(heteroarylalkynyl)-4-benzylpiperidines, J. Med. Chem., 43, 3408, 2000.
158. Whittemore, E.R., Illyin, V.I., and Woodward, R.M., Electrophysiological characterization of CI-1041 on cloned and native NMDARs, Soc. Neurosci. Abstr., 26, 527, 2000.
159. Borza, I. et al., Indole-2-carboxamides as novel NR2B selective NMDAR antagonists, Bioorg. Med. Chem. Lett., 13, 3859, 2003.
160. Gregory, T.F. et al., Parallel synthesis of a series of subtype-selective NMDAR antagonists, Bioorg. Med. Chem. Lett., 10, 527, 2000.
161. Tamiz, A.P. et al., Structure-activity relationship of N-(phenylalkyl)cinnamides as novel NR2B subtype-selective NMDAR antagonists, J. Med. Chem., 42, 3412, 1999.
162. Alanine, A. et al., 1-Benzyloxy-4,5-dihydro-1H-imidazol-2-yl-amines, a novel class of NR1/2B subtype selective NMDAR antagonists, Bioorg. Med. Chem. Lett., 13, 3155, 2003.
163. Pinard, E. et al., 4-Aminoquinolines as a novel class of NR1/2B subtype selective NMDAR antagonists, Bioorg. Med. Chem. Lett., 12, 2615, 2002.
164. Paoletti, P., Ascher, P., and Neyton, J., High-affinity zinc inhibition of NMDA NR1-NR2A receptors, J. Neurosci., 17, 5711, 1997.
165. Chen, N., Moshaver, A., and Raymond, L.A., Differential sensitivity of recombinant N-methyl-D-aspartate receptor subtypes to zinc inhibition, Mol. Pharmacol., 51, 1015, 1997.
166. Christine, C.W. and Choi, D.W., Effect of zinc on NMDAR-mediated channel currents in cortical neurons, J. Neurosci., 10, 108, 1990.
167. Aniksztejn, L., Charton, G., and Ben-Ari, Y., Selective release of endogenous zinc from the hippocampal mossy fibers in situ, Brain. Res., 404, 58, 1987.
168. Assaf, S.Y. and Chung, S.H., Release of endogenous Zn2+ from brain tissue during activity, Nature, 308, 734, 1984.
169. Paoletti, P. et al., Molecular organization of a zinc binding N-terminal modulatory domain in a NMDAR subunit, Neuron, 28, 911, 2000.
170. Evans, R.H., Francis, A.A., and Watkins, J.C., Selective antagonism by Mg2+ of amino acid-induced depolarization of spinal neurones, Experientia, 33, 489, 1977.
171. Nowak, L. et al., Magnesium gates glutamate-activated channels in mouse central neurones, Nature, 307, 462, 1984.
172. 2+ of NMDA responses in spinal cord neurones, Nature, 309, 261, 1984.
173. Wollmuth, L.P. and Sobolevsky, A.I., Structure and gating of the glutamate receptor ion channel, Trends Neurosci., 27, 321, 2004.
174. Lodge, D. and Johnson, K.M., Noncompetitive excitatory amino acid receptor antagonists, Trends Pharmacol. Sci., 11, 81, 1990.
175. Huettner, J.E. and Bean, B.P., Block of N-methyl-D-aspartate-activated current by the anticonvulsant MK-801: selective binding to open channels, Proc. Natl. Acad. Sci. USA, 85, 1307, 1988.
176. Anis, N.A. et al., The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate, Br. J. Pharmacol., 79, 565, 1983.
177. 2+ and channel blockers by a single amino acid substitution in the N-methyl-D-aspartate receptor, J. Biol. Chem., 268, 410, 1993.
178. Wong, E.H. et al., The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist, Proc. Natl. Acad. Sci. USA, 83, 7104, 1986.
179. Gill, R., Foster, A.C., and Woodruff, G.N., Systemic administration of MK-801 protects against ischemia-induced hippocampal neurodegeneration in the gerbil, J. Neurosci., 7, 3343, 1987.
180. Monaghan, D.T. and Larson, H., NR1 and NR2 subunit contributions to N-methyl-D-aspartate receptor channel blocker pharmacology, J. Pharmacol. Exp. Ther., 280, 614, 1997.
181. Parsons, C.G., Danysz, W., and Quack, G., Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist: review of preclinical data, Neuropharmacol., 38, 735, 1999.
182. Iversen, L.L. and Kemp, J.A., Non-competitive NMDA antagonists as drugs, in The NMDAR, Oxford Press, Oxford, 1994.